Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.

@article{Abergel2016LedipasvirPS,
  title={Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.},
  author={Armand Abergel and Sophie M{\'e}tivier and Didier Samuel and Deyuan Jiang and Kathryn Kersey and Phillip S. Pang and Evguenia S. Svarovskaia and Steven J. Knox and Veronique Loustaud-Ratti and Tarik Asselah},
  journal={Hepatology},
  year={2016},
  volume={64 4},
  pages={1049-56}
}
UNLABELLED Genotype 4 hepatitis C virus (HCV) was considered difficult to treat in the era of pegylated interferon-alpha (Peg-IFN-α) and ribavirin regimens. We evaluated the efficacy and safety of therapy with the nonstructural (NS) 5A inhibitor, ledipasvir, combined with the NS5B polymerase inhibitor, sofosbuvir, in patients with HCV genotype 4. In this phase 2, open-label study, 44 patients (22 treatment naïve and 22 treatment experienced) received a fixed-dose combination tablet of 90 mg of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Ombitasvir/paritaprevir/ritonavir with ribavirin achieves high sustained virologic response (SVR) rates in Egyptian adults with chronic HCV genotype 4 infection

  • I Waked, G Shiha, RB Qaqish, G Esmat, A Yosry, W Doss
  • J Hepatol
  • 2016
1 Excerpt

COMMAND-4 study team. Randomized controlled trial of the NS5A inhibitor daclatasvir plus peginterferon and ribavirin for HCV genotype-4 (COMMAND-4)

  • C H ezode, L Alric, A Brown, T Hassanein, M Rizzetto, M Buti
  • Antivir Ther (Lond) 2015;21:195-205
  • 2015

Efficacy and safety of ombitasvir / paritaprevir / ritonavir co - administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis ( AGATEI )

  • T Asselah, TI Hassanein, RB Qaqish, JJ Feld, C Hezode, Stefan Zeuzem
  • HEPATOLOGY
  • 2015

Efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis (AGATE-I). HEPATOLOGY 2015;62:563A

  • T Asselah, TI Hassanein, +4 authors Stefan
  • 2015

Similar Papers

Loading similar papers…